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Executive Summary
Pharmacists are known for their expertise with medications and are the first
medical professionals that many patients seek for their day-to-day concerns. The
importance of understanding one’s medication and having appropriate oversight over the
regimen cannot be understated. There is exists a method, known as Medication Therapy
Management (MTM), with which pharmacists can ensure medication therapy safety and
appropriateness via patient interview and receive reimbursement from third-party payers
like insurance companies. However despite this, MTM is not a widely known service
amongst eligible patients.
This study focuses on the process of MTM in UK Healthcare outpatient clinics and
works to determine the main barriers between the idea and implementation of MTMs.
Survey data was collected from ambulatory care pharmacists regarding their opinions on
MTMs in order to determine whether or not a workflow solution would address the current
lack. The responses regarding the barriers collected suggest that there is opportunity for
a process-driven solution in the realm of outpatient MTM and that a newly developed
workflow could facilitate the introduction of MTM into different realms of patient care such
as during the transitions-of-care period. Additionally, utilizing time estimates, a time
saving process has the potential to reduce the institutional cost of conducting MTMs by
nearly half – possibly allowing the service to become profitable from a solely financial
standpoint. The study highlights both the desire for pharmacists to provide a service they
find value in as well as some of the external factors regarding MTM that will need to be
addressed on a whole.
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Background
The field of healthcare is ever growing, as is the push towards proactive patient care.
Patients are now expected by their healthcare team of medical professionals to invest
and participate in their own care rather than observing from the sidelines (Barry et al.,
2012). The previous doctor-patient relationship, where decision making rested solely in
the hands of the doctor, has changed due to patient dissatisfaction related to decisions
they disagree with or were not informed about; both of which subsequently led to failure
of therapy (Vermeire et al., 2001). As the number of sources for information grows in both
print media and on the internet, the question of whether or not this movement towards
patient engagement will be beneficial comes down to health literacy. Health literacy refers
to “a set of skills that people need to function effectively in the health care environment”
(Berkman et al., 2011). These skills include but are not limited to the following: the ability
to read and understand text, to locate and interpret information in a document, to use
quantitative information for tasks, to follow directions on medication regimen and to speak
and listen effectively (Berkman et al., 2011). According to various studies, low health
literacy has not only been associated with increased hospitalizations, but also with lower
ability to take medication appropriately and lower probability of engaging in preventative
services (Berkman et al., 2011).

To combat low health literacy and promote movement towards patient-oriented
care, pharmacists are being asked to take increasingly larger roles in patient-centered
care by leveraging any extra time the patient may have, to further educate them on their
medications. Pharmacists are traditionally seen as experts of medication but are
Tao
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perceived differently based on where patients encounter them. In the outpatient setting,
meaning locations such as retail stores or long-term care clinics, pharmacists are often
seen solely as dispensers of medication, despite being the first contact for patients’ health
questions and the last check of clinical appropriateness for medications. Inpatient (or
hospital) pharmacists may be relatively unknown to the public but have an equal part in
a patient’s care as outpatient pharmacists – some will perform a similar job duty of
checking and dispensing medications while others will work with doctors to develop plans
of care for patients. Although the push for pharmacy involvement is new, the process is
not – traditionally there are three prime questions used to address new prescriptions a
patient has received, namely; “what did your doctor tell you the medication is for”, “how
did your doctor tell you to take the medication”, and “what did your doctor tell you to
expect” (Wertheimer, 1996). These three questions would eventually grow into the
concept now known as Medication Therapy Management (MTM).

Figure 1: Outpatient vs. Inpatient pharmacist-patient interaction
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Medication Therapy Management
The history of MTM dates back to the 1990’s where it was referred to as “pharmaceutical
care”. A consensus definition for MTM was established in 2005 by the American
Pharmacists Association (APhA), a national pharmacist organization, and in 2008 billing
codes became available for providers to receive monetary compensation or
“reimbursement” for these services (Viswanathan et al., 2015). Providers are distinctly
defined medical professionals who are given the ability to bill governmental programs
such as Medicare and Medicaid – the definitions of a “provider” varies from state to state.
Medicare, the government provided health insurance for the elderly and disabled,
established laws in order to further the provision of MTM to the patients it covers. Within
Medicare there are different “parts” offered by the government: Part D involves coverage
for prescription medication and pharmacy benefits in the outpatient setting (Centers for
Medicare & Medicaid Services, 2017).

Under the Centers for Medicare and Medicaid Services (CMS), the Administrative
Committee of the Federal Register established drug utilization management, quality
assurance, and medication therapy management programs via 42 CFR 423.153. From
this, the current definition of MTM has been established {Table 1}. Insurance companies
who contract with CMS to provide specifically defined MTM programs in exchange for
reimbursement are termed “Part D sponsors”. These MTM programs are designed for
certain Medicare Part D patients who have various complex medical conditions or are on
a significant amount of medications {Table 1}. MTM involves a large variety of services
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including immunizations, anticoagulation management, and medication therapy reviews
(Viswanathan et al., 2014).
Table 1: Requirements of an MTM program
Per §423.153(d), a Part D sponsor must have established an MTM program that…
 Is designed to ensure that covered Part D drugs prescribed to targeted
beneficiaries are appropriately used to optimize therapeutic outcomes through
improved medication use
 Is designed to reduce the risk of adverse events, including adverse drug
interactions, for targeted beneficiaries
 May be furnished by a pharmacist or other qualified provider
 May distinguish between services in ambulatory and institutional settings
 Must be developed in cooperation with licensed and practicing pharmacists
and physicians
Targeted Beneficiaries are enrollees in sponsor’s Part D plan who meet all of the
following
 Have multiple chronic diseases, with three chronic diseases being the
maximum number a Part D plan sponsor may require for targeted enrollment
 Are taking multiple Part D drugs, with eight Part D drugs being the maximum
number of drugs a Part D plan sponsor may require for targeted enrollment
 Are likely to incur (for 2012 and subsequent year) an amount greater than or
equal to $3000 in annual Part D drug costs, increased by the annual
percentage specified in §423.104(d)(5)(iv) – [annual percentage increase for
each year is equal to the annual percentage increase in the consumer price
index for all urban consumers for the 12-month period ending in July of the
previous year]
Legal Information Institute. (2015, February 12). 42 CFR 423.104.
https://www.law.cornell.edu/cfr/text/42/423.104#d_5_iv (Last accessed on 12/13/17).

From

Comprehensive Medication Reviews
One of the key services within the larger category of MTM are Comprehensive Medication
Reviews (CMRs). A CMR is an involved process where the patient’s medication history,
current regimen, medication problems, and needed interventions are compiled into one
take-home packet. CMS has an expected definition for this but does not outline the
requirements to the same degree as it has with MTM. The take-home packet is officially
termed the “MTM Program Standardized Format” or Form CMS-10396. This packet is the
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physical set of documents that CMS requires be delivered to the patient in order for either
the pharmacist or the Part D sponsor to collect reimbursement (Centers for Medicare &
Medicaid Services 2012). A typical CMR begins with reaching out to the patient with the
offer and a brief description of the process. If the offer is accepted, the pharmacist will
conduct an interview with the patient to confirm the patient’s current medication history,
screen this developed list for any interactions or safety concerns, and address any
concerns that the patient may have regarding their medication. Although the interview
may occur over the phone, it is preferable to have it take place in-person given potential
miscommunication through lack of non-verbal cues. The process on a whole can take
from thirty to ninety minutes dependent on the complexity of a patient’s case. If the offer
is declined or the patient is unable to be reached with at least three attempts, then the
pharmacist will note this for documentation as well.

This service is increasingly being recognized as beneficial for preventing adverse
drug events, improving patient understanding, and aiding appropriate medication usage
(Viswanathan et al., 2014). Additionally, Part D sponsors have a strong financial incentive
to encourage pharmacists to complete these CMRs. Part D sponsors are evaluated by
CMS on the percentage of eligible patients whom have received the service. These
ratings take the form of “star ratings” which are used by Medicare patients when deciding
upon a Part D health insurance plan and company. Despite this, the service has not
become a frequent part of pharmacists’ workload due to the onerous steps involved and
inadequate reimbursement obtained.
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Figure 2: Insurance and Pharmacy Network

Whereas Part D sponsors are being evaluated by CMS on CMR completion
percentages, retail pharmacies are only loosely tied into the star-rating system. Retail
pharmacies are involved in a Part D sponsor’s network as the sponsor will designate
specific pharmacies the patient must pick-up their medications from in order to have them
covered by the sponsor’s Medicare plan. Thus if a Part D sponsor’s star rating is
negatively affected, it follows that fewer patients would want to select the sponsor’s
particular Medicare plan and the designated pharmacies would receive fewer patients.
As such, Part D sponsors will often use CMR completion percentage as a negotiating tool
with their contracted retail pharmacies. However, for a retail pharmacy, potential losses
in revenue via contract along with the additional revenue provided by the Part D sponsors
for conducting CMRs have not proved to be crucial for daily operations.

Tao

9

Outpatient CMRs
Currently, CMRs are mainly conducted in the outpatient setting – retail pharmacies
encourage their pharmacists to offer CMRs to patient over the phone and during all points
of

patient-pharmacist

contact. Web-based

administration

companies

such

as

OutcomesMTM or Mirixia contract with multiple Part D sponsors to provide an efficient
way to connect pharmacy service to a source of revenue. These companies will compile
a broad summary of what the patient is likely taking – in normal course of business,
pharmacies request reimbursement from Part D sponsors for the drugs dispensed that
are covered by the patient’s insurance plan. From the complied record of dispenses, an
estimation of the patient’s medication history is derived. This list is not necessarily
complete as the patient may be taking over-the-counter or prescription medications that
were not billed to a Part D sponsor. With this preliminary list, the web-based
administration companies provide a web form for pharmacies to validate with patient
information after the patient interview portion has been completed. The pharmacist notes
any interventions made, as well as concerns brought up by the patient, in the form. The
web-based administrative companies then take all information submitted by the
pharmacist and reshape it into the MTM Program Standardized Format as required by
CMS. At this point, the pharmacist is responsible for delivering this constructed take-home
packet to the patient.

Each of the Part D sponsors will review the web forms submitted by the web-based
administration companies and pass on a portion of the larger reimbursement to them.
Tao
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These companies in turn pass a portion of their reimbursement onto pharmacies as fee
for the legwork. The portion that pharmacies receive ends up being around $50-100
(OutcomesMTM, 2017). Considering that OutcomesMTM reported a Return-onInvestment per pharmacist-identified cost-savings intervention of $656.39 in its 2016
MTM Trends Report, the $50-100 given per patient can be argued as inadequate for the
work’s value (OutcomesMTM, 2016).

Outpatient retail pharmacists have the most patient interaction opportunities out of
all facets of the profession. However, as stated before, the provision of CMRs is not a
heavily marketed service by retail pharmacies. This is because the reimbursement fails
to make up for the lack of available time and interest in CMRs for both the pharmacist
and the patients. Additionally, there is an ongoing time struggle between patients who
demand that their medications be affordable and filled quickly versus pharmacists who
are obligated to ensure clinical appropriateness and safety. Patients will often not see the
benefit in a service such as CMR given that benefits are typically not immediate, whereas
the hassle of an in-depth interview is readily apparent – the scheduling of time, the
previously described process of compiling a medication list, the attention that a medically
complicated patient requires, etc. Pharmacists may instead focus on the medication
checking and dispensing side of the job in order to appease their customers – even those
who recognize the patient benefits in CMRs may be hesitant to devote time to it given
that they are not correctly incentivized.
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Inpatient CMRs
CMS utilizes a different payment program with Medicare for the inpatient setting. Instead
of Part D, Medicare Part B covers services provided by the hospital, durable medical
equipment, as well as some preventative services. Programs similar to CMRs have been
suggested as valuable initiatives in the inpatient setting. Although CMS allows Pharmacist
Clinicians to receive Medicare Part D reimbursement, CMS does not currently recognize
Pharmacist Clinicians as healthcare

providers eligible

for Medicare

Part B

reimbursement, thus hospitals often must work with third-party payers to ensure that
reimbursement for MTM services is possible (UNM Medical Group, 2014).

Inpatient pharmacists have a different angle with relation to patient care as their
degree of patient interaction is limited to the patient’s stay in the hospital. Pharmacists
have similar time pressures as their retail counterparts but are not confronted as often by
the patient. The hospital would be an ideal setting for CMRs given that the patient is more
readily available for consultation, their medication history is up-to-date pursuant to other
pharmacy-related services, and consultation with other providers regarding complex
interventions is facilitated by proximity. The patient is unable to leave as placed discharge
orders do not mean that the patient is allowed to physically leave the hospital; a
pharmacist conducting a CMR at this time would have a captive audience here, bypassing
the time issue that arose in the outpatient scenario. The main issue with CMRs in the
inpatient setting is the complete lack of reimbursement from Medicare for pharmacist
work. As mentioned before, pharmacists are not eligible for reimbursement from Medicare
Part B due to lack of provider status and Part D does not apply to the inpatient setting.
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Transitions of Care
The time between a patient’s hospital stay after discharge (hospital orders that declare a
patient fit for leaving the hospital) and returning to home is defined as the “transitions of
care” period. Transitions of care represents the transference of responsibility from the
inpatient providers to the patient and their primary care provider. This time frame proves
to be fraught with errors given that patients will have “prescription medicines commonly
altered at this transition point” with “[s]elf-care responsibilities [that] also increase in
number and importance” (Kripalani et al., 2007). According to Kripalani et al., 49% “of
hospitalized patients experience at least 1 medical error in medication continuity,
diagnostic workup, or test follow-up”. When looking specifically at adverse drug events,
they are reported to occur in 19-23% of patients. Due to the barriers present in the
outpatient realm and difficulty faced in the inpatient setting, this alternative time period
has been suggested for conducting these MTM services.

This short time period technically falls under the outpatient realm. The responsibility of
the patient’s care has been transferred from the hospital staff to the patient’s primary care
provider despite the fact that the patient physically resides in the hospital. Patients often
remain in their room and are not allowed to leave until final preparations by various
hospital staff have been made as discharge orders put in by a doctor only signify the need
for staff to arrange follow-up appointments, transportation, financial matters, printing and
preparation of all papers, and a final discussion with the patient to ensure understanding
(UpToDate, 2017). Although the proposal of CMR in this time frame is relatively
unexplored, the idea of pharmacy providing a service during this time frame is not.
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Hospital-based retail pharmacies, those which serve an outpatient population but are
either affiliated or owned by the hospital center, have developed programs to provide
recently discharged patients with their first dose of new medications (UK HealthCare
Pharmacy Services, 2017). The provision of a CMR during this same period would thus
be conducting an outpatient service. This combines the benefits of both the outpatient
and inpatient settings to negate the detriments of each – the patient is available for this
service given their physical location in the hospital and pharmacists are able to receive
reimbursement according to Part D MTM guidelines.

The remaining issues with providing CMR services during the transitions of care
timeframe includes the pharmacist’s availability to conduct them and the financial benefit
of the service itself. From a strictly financial standpoint, each successfully conducted CMR
will net a pharmacy between $50 and $100 (OutcomesMTM, 2017). Adding the factors of
time required to aggregate a patient’s medication history, interview, develop a relevant
action plan, and submit the documentation, the premium of a pharmacist’s time may
outweigh the current dollar amount provided. This calculation is slightly blunted by the
fact that hospital-based pharmacies are often interested in long-term patient health given
that it may reduce hospital costs in other areas – shown by values such as Return-onInvestment (OutcomesMTM, 2016). One example of this cost is patient readmission,
where CMS will reduce Medicare payments for hospitals with excess readmissions
(Centers for Medicare & Medicaid Services, 2015). The overall goal would be to distribute
the work needed by dividing a transitions-of-care CMR into portions that can be
conducted via a pharmacy technician against portions that require a pharmacist’s
Tao
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expertise. This would allow for pharmacists to efficiently allocate their time while ensuring
that the venture remains profitable for the hospital.

At the University of Kentucky Chandler Medical Center, the transitions-of-care CMR is
currently being explored as a viable realm for CMRs. In doing so, the University of
Kentucky aims to improve patient outcomes while increasing total reimbursement
received ensuring the long-term viability of providing CMRs. Given the undeveloped
nature of CMR application in this timeframe, there have not yet been proven methods for
providing these services. The nature of this research stems from the need to develop one
such possible method in order to address the remaining issue of financial sustainability
and potential additional health benefits that may result. The first step of this research
involves polling pharmacists in the retail setting about the significance of CMRs in order
to identify potential barriers that will counteract this process.
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Problem Statement
Both the outpatient and the transitions-of-care realm will be considered. Although
the patient health benefits and the financial benefits for Part D sponsors are widely known,
CMRs have not become widely used in the outpatient area. This research endeavors to
pin down the most influential reasons as to this non-use. These barriers fall into a few
broad categories. First, there is the question of value, both on the side of the pharmacist
and the side of the patient. The perceived value of the service in both parties in terms of
health or financial benefit could largely affect the amount of CMRs provided. Logically,
patients who understand the benefits would be more likely to request the service and
pharmacists would be more likely to seek out patients who need them. Secondly, the time
needed to conduct a CMR is a potential significant barrier. A service that requires
preparatory work in addition to an interview consumes time that a retail pharmacist could
use otherwise with checking prescriptions, patient counseling, or working out insurance
issues, not to mention the time burden on the patient themselves. Communication and
patient interaction is the third proposed barrier which comes into play in contacting
patients, informing them of the service, and within the interview itself. This is not as readily
apparent as value or time however the importance of patient engagement and
participation in the process merits lack of these as potential problems. Finally from the
perspective of the pharmacist, insufficient resources or a lack of understanding of the
process can prevent effective utilization of CMRs. All of these problems carry over from
the current retail setting to the transitions-of-care setting and thus are important to
address before implementation of any new process.
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Literature Review
The literature around this inquiry of developing a workflow for Medication Therapy
Management programs in the outpatient, transitions-of-care setting has not been
previously explored. There have been previous studies that look into the benefit of MTM
(which have subsequently been used to justify the requirement placed by the Centers for
Medicare and Medicaid), however these are limited to the efficacy and outcomes provided
from these programs in the pure outpatient setting. The general lack of studies regarding
the efficacy of MTMs is likely due to confounding factors. A patient who has received an
MTM service such as a CMR will more than likely have more providers and other
interventions attempted at the same time given that having multiple chronic conditions is
listed as a requisite to be a targeted beneficiary per Medicare. To provide a better
understanding of the topic, specific references have been highlighted as core sources
(Table 2).

Table 2: Key Literature Cited
Author(s)
Centers for
Medicare
and
Medicaid
Services

Kripalani,
Jackson,
Schipper,
Coleman

Tao

Document
Medication Therapy
Management:
https://www.cms.go
v/Medicare/Prescrip
tion-Drug-Coverage
/PrescriptionDrugC
ovContra/MTM.html
Promoting effective
transitions of care
at hospital
discharge: a review
of key issues for
hospitalists

Date
10 /
2017

09 /
2007

Background Relevance to Capstone
Definition of MTM program including
professional guides and memos for
hospitals, providers, and patients. Contains
what the US government requires of thirdparty payers in
order to obtain
reimbursement and the benefits they
receive in doing so.
Looks into the effects of transitioning
patients from hospital to outpatient care; the
consequences and strategies to improve the
process. Denotes medication reconciliation
as an effective method to improve patient
care during TOC.
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UNM
Medical
Group, INC.

Medication Therapy 07 /
Management
2014

Vermeire,
Hearnshaw,
Royen,
Denekens

Patient adherence
to treatment: three
decades of
research. A
comprehensive
review.

Viswanathan Medication therapy
et. al.
management
interventions in
outpatient settings:
a systematic review
and meta-analysis
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10 /
2001

01 /
2015

Different states have different regulations on
the definition of a “medical provider”. This
protocol contains the method for billing for
an institution in New Mexico, a state which
has
such
modified
definitions
for
pharmacists, via a variety of inpatient
settings via CPT codes which are applied to
Medicare Part D.
Literature
review
on
terminology
differentiating compliance, concordance,
and adherence; discusses the results of
poor adherence on patient health in general.
Does not contain any studies or statistical
analysis but references and summarizes the
effects of multiple studies and provides
background as to potential role for MTM.
Meta-analysis
determining
effect
of
outpatient MTM on various health outcomes
vs standard of care. Study observed
statistically significant improvement in
medication appropriateness and adherence
in terms of doses taken. However, evidence
was insufficient to determine significant
effect on health outcomes. Provides
evaluation on methods to improve future
analysis, explanation of difficulty in isolating
benefits, as well as methods to improve
MTM process.
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Research Design
The purpose of this study is to evaluate a proposed workflow for conducting CMRs and
analyze the effects of the constructed survey tool on this workflow. However, given that
the implementation of the survey tool is reliant on the institution rather than personal
research, a survey tool was also utilized to capture pharmacist opinions towards MTMs
in an attempt to provide usable data. Both surveys were constructed in REDCap
(Research Electronic Data Capture) – a web-based application developed by Vanderbilt
University specifically for capturing data used in research studies (REDCap, 2017). The
survey consisted of three distinct portions. The first section focused on beliefs regarding
barriers to conducting MTMs with a question asking participants to rank their top three
perceived barriers. The second section was for pharmacists who have conducted MTMs
to estimate the time needed for the process. Finally, the third section utilized a Likert
Scale to evaluate various statements regarding the effect of MTM’s on pharmacists and
patients. The breakdown of the survey is attached (Appendix A). In terms of analysis,
these results were used to gauge the need for a new workflow for MTMs.

The workflow tool will serve as a hassle-free and efficient manner for gathering
responses. Participants do not need any log-in credentials given that the tool uses a
universal web address. Additionally, the tool contains a wide range of programmed
question formats such that it is relatively easy for an administrator to use in case the need
for further tool development arises. The survey tool was designed in order to shift a portion
of the workload from pharmacists to pharmacy technicians and overcome the barrier of
additional technological burden for the pharmacists. In doing so, it is hoped that
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pharmacists will engage in more CMRs due to the lessened time burden. This proposed
workflow would however increase the overall workload of pharmacy technicians. This
program is in plans to be piloted with patients treated by physicians in the cardiovascular
clinic at UK Healthcare who were designated by OutcomesMTM (the third-party web
application connecting insurance companies and UK Healthcare) as needing a CMR.

Previous Workflow
The term “previous workflow” is utilized to describe the workflow that is to be replaced by
the proposed tool. A graphic has been included to help delineate between the previous
and proposed workflows [Figure 3, Panel A]. Hospital-admitted patients are targeted for
CMR when their discharge orders have been placed. On a twice-weekly basis, a
pharmacist merges the CMR eligible list provided from OutcomesMTM with the current
inpatient list – this allows the pharmacist to determine which CMR eligible patients are
currently in the hospital. They then consolidate the patient’s admitting medication history
and any changes to their medication regimen that have been made during their stay. The
pharmacist then fills out the form on the OutcomesMTM web-application with this
information, creates a printable version and conducts the CMR with the patient by their
bedside – they would correct any errors, fill out any missing information, as well as convey
any medication-related problems that are present along with their recommended
interventions for the patient. Afterwards the pharmacist completes the OutcomesMTM
form using the information they had obtained from the interview and sends the patient (or
designated recipient) their action plan packet.
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Figure 3: Previous and Proposed Workflows
A.

B.
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Piloted Workflow
The piloted workflow differs from the one above with the inclusion of the REDCap survey tool and
utilization of a pharmacy technician [see Figure 3, Panel B]. In this figure, the administrative
pharmacist may at times act as the MTM pharmacist as well. After consolidating the patient’s
medication history, the technician would email both the printable OutcomesMTM form and the
REDCap survey link to the responsible pharmacist. After the pharmacist conducted the CMR,
they would utilize the REDCap survey tool to provide the relevant information and notify the
designated technician of its completion. Using the results from the REDCap survey, the technician
would complete and submit the OutcomesMTM form, then send the patient (or designated
recipient) their action plan packet.

Data Collected
Following implementation of the piloted workflow, the time required for completion of MTM’s was
compared against the predicted times from the opinion survey as well as the recorded time from
the sample pharmacist for Previous Workflow processes. Data analysis will focus mainly on the
data obtained from the pharmacist opinion survey with time data used to determine if the Piloted
Workflow is in fact an overall benefit to the process.
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Results
The survey was sent out via a listserv for UK Healthcare “Ambulatory Pharmacists” with two
weeks allotted for response time. Of the potential 36 pharmacists eligible to answer, there were
19 responses collected for a response rate of 52.8%. The survey results are listed below by
survey section.
Section 1: Barrier Identification

An initial question asked the respondent if they believed there were any barriers to conducting
MTMs. If yes, the survey asked the pharmacists to rank the top three barriers in the list in order
of significance. These barriers have been classified relative to the problem to which they relate.
The following table provides the number of times each barrier was ranked. All 19 pharmacists
provided responses for this section. The total score was calculated via a linear weight; each rank
#1 counted as 3 points, #2 as 2 points, and #3 as 1 point.
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Table 3: Barrier Perception Ranking (n=19)
Barriers

Related
Problem

Times
ranked
#1

Times
ranked
#2

Times
ranked
#3

Total
Score

Difficulty Integrating MTMs into Normal
Pharmacy Workflow

Time

4

5

1

23

Time Required of Pharmacy Personnel to
Conduct MTM

Time

3

3

3

18

Difficulty in Engaging Patients

Communication

3

2

2

15

Difficulty in Contacting Patients due to Social
Issues

Communication

4

0

2

14

Value

1

2

3

10

Time

2

1

1

9

Lack of Private Counseling Area

Resource

1

1

1

6

Difficulty in Identifying Eligible Patients

Resource

0

2

0

4

Lack of Interface of Pharmacy System (i.e.
Scriptpro) with Outcomes

Resource

1

0

1

4

Value

0

0

3

3

Complex Web-Submission Interface (i.e.
Outcomes MTM)

Resource

0

1

0

2

Lack of Pharmacy Resources and Support

Resource

0

1

0

2

Unfamiliarity with MTM process

Resource

0

1

0

2

Time/Value

0

0

1

1

Resource

0

0

1

1

Value

0

0

0

0

Insufficient Patient Interest
Time Required of Patient to Conduct MTM

Insufficient Patient Financial Benefit

(Other) “Financial gain from completing an MTM
- hard to understand the utility with such nominal
payment; time to conduct an MTM does not
justify the 'payment'”
Parking and Transportation Issues for Patients
with Appointments
Insufficient Patient Health Benefit
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Table 4: Barrier Perception Ranking: Respondents and Total Score (n=19)
Pharmacist

Score for
Communication

Score for
Resource

Score for Time

Score for Value

Highest
Problem

1

0

1

3

2

Time

2

0

0

5

1

Time

3

0

0

5

1

Time

4

1

2

3

0

Time

5

1

2

3

0

Time

6

3

0

3

0 Communication
/ Time

7

0

5

1

0

Resource

8

0

1

5

0

Time

9

1

0

5

0

Time

10

0

2

4

0

Time

11

3

2

0

1 Communication

12

0

5

1

0

Resource

13

0

0

5.5*

0.5*

Time

14

3

0

0

3 Communication
/ Value

15

5

1

0

0 Communication

16

3

0

2

1 Communication

17

3

0

2

1 Communication

18

3

0

1

2 Communication

19

3

0

2

1 Communication

29

21

50.5

Total

13.5

Time

*Respondent provided a response in “Other” that is classified as both time and value based.
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Section 2: Timing
This section of the survey requested respondents who had previously conducted an MTM to
estimate the time needed for each step in the process. Of the 19 respondents, one provided no
response, one answered no, and one answered yes but did not provide any times.
Table 5: Average Estimated Time for MTM Process (n=16)
Step in Process

Average
Time
(minutes)

Standard
Deviation
(± minutes)

Minimum
Estimate
(minutes)

Maximum
Estimate
(minutes)

Attain Patient Engagement

16.25

9.4

5

30

Pre-Interview Preparation

25.63

17.4

5

60

Patient Interview

30

14.61

10

60

Documentation and
Submission

20

10.17

10

45

91.875

30.28

30

180

Total Process

Section 3: Barrier Statements
The third and final section of the survey contained a variety of statements designed to reflect the
barriers of Section 1. The questions were set-up via a 5-point Likert Scale with results as follows.
Of the 19 survey respondents, the sixteen who completed Section 2, also completed this portion
of the survey. Note: Reversed questions are denoted and have had both their question and
responses in table reversed to reflect this such that all results of “Strongly Disagree” and
“Disagree” reflect indication of the topic as a barrier. Total Score in this Section was calculated in
a similar fashion to Table 3, with Strongly Disagree selections meriting a score of 5, Disagree
equivalent to a score of 4, etc.
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Table 6: Barrier Perception via Likert Scale Statements (n=16)
Statement

Strongly
Disagree

Disagree

Neither
Agree
nor
Disagree

Time /
Value

5

8

3

0

0

66

Communication /
Value

6

5

4

1

0

64

[Reversed] With third party payers
holding back reimbursement based
on MTM performance, there is not
strong financial incentive to complete
MTMs.

Value

5

7

1

3

0

62

My colleagues have a positive
disposition towards MTMs.

Value

2

6

6

2

0

56

Time

2

5

8

1

0

56

From a solely financial standpoint,
MTMs are profitable.

Value

2

2

7

5

0

49

[Reversed] The process of
documentation does not require too
much time for MTMs to be beneficial.*

Time /
Value

1

6

4

4

0

49*

Conducting MTMs is a beneficial use
of my time.

Time /
Value

1

1

5

6

3

39

[Reversed] MTMs are a useful
component of a pharmacist’s
responsibilities.

Value

1

1

3

10

1

39

Because of the lack of provider
status, MTMs provide a strong
opportunity for pharmacists to directly
affect patient care.*

Value

0

2

4

8

1

37*

APPE students and interns should be
assigned to do more MTMs.

Resource

1

0

4

7

4

35

[Reversed] MTMs will be an important
part of a pharmacist’s activities in the
future.

Value

1

0

4

7

4

35

MTMs are a vital portion of patient care.

Value

0

2

2

8

4

34

More MTMs would be conducted if
pharmacists only needed to conduct
the patient interview and develop the
action plan.

Time

0

0

5

7

4

33

Resource

0

1

0

8

7
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[Reversed] Reimbursement for MTMs
does match the work required.
Patients understand the importance
of MTMs.

[Reversed] There are not more
efficient methods of providing patient
care than MTMs.

I fully understand the process of
conducting MTMs.

Related
Problem

Agree

Strongly
Agree

Total
Score

*One of the sixteen respondents chose not to provide a response to this statement. Total score for this statements is artificially
lower as a result.
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Table 7: Barrier Perception via Likert Scale Statement: Respondents and Average Score
(n=16)
Pharmacist

Score for
Communication

Average Score for
Resource

Average Score for
Time

Average Score for
Value

(1 statement)

(2 statements)

(5 statements)

(11 statements)

1

5

3

4

3.55

2

4

2

3.2

3.09

3

5

2

4.6

4.55

4

4

2

3.2

2.45

5

4

2

3.4

3.09

6

4

2.5

2.6

2.8*

7

5

1

3.2

3.27

8

3

1.5

2.6

2.64

9

3

1.5

2.8

2.91

10

3

2

2.6

2.73

11**

-

-

-

-

12

2

2.5

2.6

2.73

13**

-

-

-

-

14

5

2.5

3.6

3.45

15

3

1.5

2.25*

2.4*

16

5

2

3.4

3.45

17

5

1

2.4

3.09

18

4

2

2.6

2.45

19***

-

-

-

-

4

1.94

3.07

3.04

Total
Average

*Average calculated with one less field due to non-response.
**Pharmacists who did not provide response; number designation kept for consistency.
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Discussion
Overall this survey was helpful in elucidating the barriers towards conducting CMRs at the
University of Kentucky. Utilizing the total score, the top barriers that emerged were based on time
and communication rather than value or resource.
1. Difficulty Integrating MTMs into Normal Pharmacy Workflow (Time; 23)
2. Time Required of Pharmacy Personnel to Conduct MTM (Time; 18)
3. Difficulty in Engaging Patients (Communication; 15)
4. Difficulty in Contacting Patients due to Social Issues (Communication; 14)
5. Insufficient Patient Interest (Value; 10)
6. Time Required of Patient to Conduct MTM (Time; 9)

It is important to note that there were more categories for the barriers of resource and value but
that the sum of the categories would still not displace time and communication as the top barriers
in this regard [see Table 4]. The difference between the top two barriers reflects a small potential
distinction in the fix needed in the MTM process. Difficulty in integrating MTMs into the normal
workflow indicates that the pharmacists believe an efficient process can exist that will allow them
to conduct MTMs with their current workload. That being said, even without this distinction, the
pharmacists heavily rank issues with the MTM’s process over needing additional resources to
incorporate MTMs normally. Barriers number 3 and 4 indicate that pharmacists are not as
concerned over the applicability or use of MTMs.
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Utilizing the total score measure with Section 3 representing statements of barriers, a similar
trend emerges. Based on the average total score of 48, any scores below this represent an overall
agreement with the statement and lowered significance of the barrier. The most contested
statements are as follows:
1. Reimbursement for MTMs does match the work required. (Time/Value; 66)
2. Patients understand the importance of MTMs. (Communication/Value; 64)
3. With third party payers holding back reimbursement based on MTM performance, there is
not strong financial incentive to complete MTMs. (Value; 62)
4. There are not more efficient methods of providing patient care than MTMs. (Time; 56)
5. My colleagues have a positive disposition towards MTMs. (Time; 56)
These statements do not directly scale with the rankings of the survey’s first section as these
statements add the consideration of problems with pharmacy reimbursement and third-party
involvement in MTMs. The respondents maintain their desire for better patient outreach and
understanding of the benefits (shown by number 2) as well as their belief that the process is
beneficial (shown by number 4 and 5). Given that the statements were not equally weighted for
the representative problems, the average Likert Scale rating must be used for comparison
between the barriers.
-

Communication; 1 Statement = 4

-

Time; 5 Statements = 3.07

-

Value; 11 Statements = 3.04

-

Resource; 2 Statements = 1.94

The averages show that time and value considerations remain more important than those for the
amount of pharmacy given resources at hand. Together, both sections seem to indicate that the
Tao
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problems for MTM that a pharmacy department can internally address in order to have more
widespread utilization are the time needed to conduct a CMR along with communication with the
patients. I believe that the proposed workflow strikes at the heart of this issue and will prove useful
for these concerns. The tool developed correctly pinpoints time as a factor, and although
communication needs to be worked on as well, the new workflow is an internal process that can
be implemented without patient input.
The answers that the pharmacists provided for the first and third sections of the survey did
not show any statistically significant correlation with their estimation of MTM process time in the
second section. Linear regression utilization total estimated time separately against rank score
from the first section and average score from the third section did not show any significant pvalues, nor high R-square values.

Figure 4: Linear Regression: Total Time vs. Rank Score
Regression Statistics
Multiple R
R Square
Adjusted R Square
Standard Error
Observations

Intercept
Rank Score Communication
Rank Score Resource
Rank Score Time
Rank Score Value

Tao

0.276954
0.076704
-0.23745
42.19848
16

Coefficients
38.51176
11.43104
11.78628
8.533923
0

Standard
Error
68.18928
15.12577
12.08226
12.99282
0

t Stat
0.564777
0.755733
0.975503
0.656818
65535

P-value
0.582629
0.464386
0.348566
0.523695
#NUM!

31

Figure 5: Linear Regression: Total Time vs. Statement Average Score
Regression Statistics
Multiple R
R Square
Adjusted R Square
Standard Error
Observations

0.39972128
0.159777102
-0.145758498
42.04533127
16

Intercept
Statement Communication Average
Value
Statement Resource Average Value
Statement Time Average Value
Statement Value Average Value

Coefficients
87.1414252

Standard
Error
71.8864

t Stat
1.21221

P-value
0.250826

-14.81162735
5.057105822
-33.83117581
51.9238278

15.65929
24.29886
41.13095
44.30084

-0.94587
0.208121
-0.82252
1.172073

0.36453
0.838938
0.428249
0.265927

With regards to the estimations of time for the process, the average estimation for a complete
CMR was around 92 minutes, with only 30 minutes designated as time spent during a patient
interview. If the pharmacist is considered needed for the patient interview and half of the time
spent in pre-interview preparation (e.g. reviewing the patient profile), then the average time split
between technician and pharmacist would be about 50 minutes to 42 minutes respectively. At an
average salary of $13 per hour for a pharmacy technician and $50 per hour for a pharmacist, the
cost of an MTM via previous workflow of ~$77 drops to ~$46 per patient.
Figure 6: Cost per Average MTM Conducted

Time (Hours)

2
1.5
$35…

1
$76.67
0.5
0
Previous Workflow
$50/hour
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Conclusion
This study collected survey data regarding pharmacist opinions on barriers towards
conducting CMRs and has shown two major problem areas to focus on. Pharmacists appear to
have a good understanding of the benefits of CMRs and would be willing to incorporate it into
their workflow for the benefit of the patient. The developed tool that is awaiting implementation
should prove to be useful in alleviating the issue of time allotment. However, although the tool will
reduce the time spent by pharmacists on each CMR, there is no guarantee that this saved time
will be “reinvested” into CMRs or if it will be used to address the many other demands.
Additionally, the noted concerns with patient communication will likely require patient input to
improve as they involve transferring the pharmacist’s understanding of value of the CMR to the
patient.
Future directions with this research involve the collection of timing data for pharmacists
conducting CMRs with both the “previous workflow” and the proposed workflow to compare
against the estimated time data collected here. Comparison against each other would provide
further clarification on financial savings by shifting of work from pharmacist to pharmacy
technician. Additionally, research into methods of addressing the communication problem with
patients would serve as a helpful addition to the efforts on the pharmacists’ side.
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Limitations
This study’s limitations center on the number of polled pharmacists. Although the
sample size for this study was low, the survey respondents were highly representative of
the target for the developed process. This survey does not poll the pharmacists who are
considered for implementation in the new process, nor does it address the thoughts of
pharmacy technicians or patients regarding the barriers to CMRs. Additionally, there are
the traditional concerns with survey-based studies regarding the time needed for the
voluntary survey and the resulting response amounts. This study also had a lack of
directly timed data for the “previous workflow” given that only one pharmacist is currently
conducting these MTMs.
In terms of analysis, the linear modeled total score used to determine barrier
significance could be argued as not completely representative of pharmacist opinions
given the relative nature of ranking. The method used of analysis is not a replacement for
statistical analysis but provides the needed picture regarding whether or not to proceed
with process implementation.
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Appendix A: Survey
--- Page 1 --- (Consent Script)
Hello! My name is Allan Tao, I am a PY4 student at UK and am conducting this survey to better
understand pharmacy personnel opinions related towards the process of Medication Therapy Management
(MTM). I am asking for your participation in this survey to aid me with my MPA capstone research
project. If you voluntarily participate in this study you will be one of approximately 36 pharmacists at
University of Kentucky HealthCare asked to do so.
You have been asked to participate in this survey because you are a pharmacist who may
potentially be tasked with conducting MTMs in the Transitions-of-Care setting. This survey will take
approximately 10 minutes to complete and will ask about your opinions related to the workflow process
and significance of MTMs. Please note, the phrase “Medication Therapy Management” will be
considered synonymous with “Comprehensive Medication Review” for the purposes of this survey. The
information generated from this research will be used to inform ongoing local, regional and national
discussions about the value of MTMs.
To ensure all responses to the first survey on pharmacists’ opinions are anonymous, a universal
URL link has been provided to all participants. Results from REDCap will not denote any information as
to respondents’ identity. Additionally, there are no queries as to your identity in the survey.
There are no known risks associated with completing this survey. Taking part in this survey
research is completely voluntary. Your employment status will not be affected in any way, regardless of
whether you participate or not. I am not employed by University of Kentucky HealthCare. If you choose
not to participate, there will be no penalty or loss of benefits to you. If you do choose to participate, you
are free to skip any survey question that you do not want to answer and you can discontinue the survey at
any time. Although you will not personally benefit by completing the survey, the information that you
provide may help inform ongoing discussions related to the significance of
MTMs.
This study has been reviewed by the University of Kentucky Medical Institutional Review Board.
If you have questions about this study, you may call myself at 859-559-5885 or my MPA capstone
advisor, Karen Blumenschein at 859-257-5778. If you have any questions about your rights as a volunteer
in this research, you may contact the staff in the Office of Research Integrity at the University of
Kentucky at 859-257-9428 or toll free at 1-866-400-9428.
Thank you for your time and we appreciate your consideration in completing this survey.
Sincerely,

Allan Tao and Karen Blumenschein
Tao
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I understand the intent, potential risks, and anonymity of this survey and am willing to complete it.
- Yes
- No
{If no, will close survey}

--- Page 2 --Do you believe there are barriers to conducting MTMs?
- Yes
- No
{If no, skip to page 4}

--- Page 3 --Which of the following do you believe are barriers to conducting MTMs? (Select the top three barriers in
order of significance)
- Complex Web-Submission Interface (i.e. OutcomesMTM)
- Difficulty in Contacting Patients due to Social Issues
- Difficulty in Engaging Patients
- Difficulty in Identifying Eligible Patients
- Difficulty Integrating MTMs into Normal Pharmacy Workflow
- Insufficient Patient Financial Benefit
- Insufficient Patient Health Benefit
- Insufficient Patient Interest
- Lack of Interface of Pharmacy System (i.e. Scriptpro) with Outcomes
- Lack of Pharmacy Resources and Support
- Lack of Private Counseling Area
- Parking and Transportation Issues for Patients with Appointments
- Time Required of Patient to Conduct MTM
- Time Required of Pharmacy Personnel to Conduct MTM
- Unfamiliarity with MTM process
- Other:
o Free Text Box
--- Page 4 --Have you conducted an MTM in the past?
- Yes
- No
{If no, skip to page 3}
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When attempting to recruit an eligible patient for an MTM, how much time (in minutes) is needed to
attain patient engagement? Consider time required to initiate patient contact, to provide relevant
information, and to schedule an interview.
When conducting an MTM, how much time (in minutes) is needed for pre-interview preparation?
Consider time required to consolidate medication history and review patient profile.
When conducting an MTM, how much time (in minutes) is needed for the patient interview portion?
Consider time required to conduct full interview as well as develop and communicate action plan.
When conducting an MTM, how much time (in minutes) is needed for documentation and submission
process to a web-interface (i.e. OutcomesMTM). Consider time required to fill out web-form and send
take-home packet to appropriate recipient.
--- Page 5 --Please indicate your level of agreement/disagreement with the following statements using the scale
shown below:
1
2
3
4
5
Strongly Disagree
Disagree
Neither Agree nor
Agree
Strongly Agree
Disagree
(each as an individual question)
- I fully understand the process of conducting MTMs.
- MTMs are a vital portion of patient care.
- Conducting MTMs is a beneficial use of my time.
- More MTMs would be conducted if pharmacists only needed to conduct the patient interview and
develop the action plan.
- From a solely financial standpoint, MTMs are profitable.
- There are more efficient methods of providing patient care than MTMs.
- MTMs are not a useful component of a pharmacist’s responsibilities.
- My colleagues have a positive disposition towards MTMs.
- Reimbursement for MTMs does not match the work required.
- Patients understand the importance of MTMs.
- The process of documentation requires too much time for MTMs to be beneficial.
- Because of the lack of provider status, MTMs provide a strong opportunity for pharmacists to
directly affect patient care.
- MTMs will not be an important part of a pharmacist’s activities in the future.
- APPE students and interns should be assigned to do more MTMs.
- With third party payers holding back reimbursement based on MTM performance, there is strong
financial incentive to complete MTMs.
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